WEST PHARMACEUTICAL SERVICES INC
WSTNYSE · SIC 3841
$358.24
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↑ +60.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.9B
Enterprise Value
$25.6B
P/E
47.9
P/S
8.1
P/B
8.7
EV/EBITDA
30.8
PEG
—
FCF Yield
1.8%
Dividend Yield
0.2%
Revenue (TTM)
$3.2B
Net Income (TTM)
$542.7M
Free Cash Flow (TTM)
$458.0M
Gross Margin
36.3%
Operating Margin
20.3%
Net Margin
16.9%
ROE
18.1%
ROIC
19.3%
Debt / Equity
0.1
Net Cash
$318.6M
Return 1Y
+62.2%
Company profile
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The company distributes its products through its sales force and distribution network.
- CEO
- Eric M. Green
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 10,700
- Headquarters
- Pennsylvania
- Website
- westpharma.com
Management & directors
- Campbell Shane AldenSVP, Proprietary Segment
- Favorite Annette FSr. VP & Chief HR Officer
- Winters ChadVP, Chief Accounting Officer
- Poussot Rodolphe JeanSVP, Strategy & Corporate Dev
- Witherspoon CharlesVP & Treasurer
- Green Eric MarkPresident, CEO and Board Chair
- Mcmahon Robert W.SVP & Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-23
WST Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$844.9M↑ +21.0%
Diluted EPS$1.92↑ +56.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Gross profit | $767.8M | $1.2B | $1.1B | $1.1B | $998.5M | $1.1B |
| Operating income | $406.9M | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M |
| Net income | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| Diluted EPS | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Operating cash flow | $472.5M | $584.0M | $724.0M | $776.5M | $653.4M | $754.8M |
| Free cash flow | $298.1M | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Gross margin | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating margin | 19.0% | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Net margin | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $702.1M | $746.9M | $748.8M | $698.0M | $766.5M | $804.6M | $805.0M | $844.9M |
| Gross profit | $230.0M | $264.7M | $273.6M | $231.9M | $273.9M | $294.3M | $303.9M | $296.4M |
| Operating income | $126.2M | $161.3M | $159.6M | $107.0M | $153.7M | $167.6M | $156.6M | $177.1M |
| Net income | $111.3M | $136.0M | $130.1M | $89.8M | $131.8M | $140.0M | $132.1M | $138.8M |
| Diluted EPS | $1.51 | $1.85 | $1.78 | $1.23 | $1.82 | $1.92 | $1.82 | $1.92 |
| Operating cash flow | $165.0M | $180.1M | $190.1M | $129.4M | $177.1M | $197.2M | $251.1M | $89.9M |
| Free cash flow | $64.8M | $98.8M | $85.2M | $58.1M | $101.9M | $133.9M | $175.0M | $47.2M |
| Gross margin | 32.8% | 35.4% | 36.5% | 33.2% | 35.7% | 36.6% | 37.8% | 35.1% |
| Operating margin | 18.0% | 21.6% | 21.3% | 15.3% | 20.1% | 20.8% | 19.5% | 21.0% |
| Net margin | 15.9% | 18.2% | 17.4% | 12.9% | 17.2% | 17.4% | 16.4% | 16.4% |
Company news
Jul 20, 2026
Jul 17, 2026
- 3d agoISRG Q2 Earnings Beat Estimates, Stock Falls on Slow Procedure Growthfinance.yahoo.com
- 3d agoStryker Launches Mako RPS to Expand Robotic Knee Surgery Portfoliofinance.yahoo.com
- 3d agoHere's Why You Should Retain INSP Stock in Your Portfolio for Nowfinance.yahoo.com
- 3d agoGEHC Stock Up on $500M Strategic Care Alliance With Catholic Healthfinance.yahoo.com
- 3d agoXLP's Future Earnings Outlook Is Tilting Uptrefis.com
- 3d agoWhat Could Fuel a Real Turnaround for Alcoa Stock?trefis.com
- 3d agoDid West’s Expanded Daikyo Distribution Deal Reshape West Pharmaceutical Services' (WST) GLP‑1 Component Investment Narrative?finance.yahoo.com
Jul 16, 2026
- 4d agoWest Pharmaceutical Services (WST) Expands Daikyo Ties As Valuation Questions Growfinance.yahoo.com
- 4d agoDanaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?finance.yahoo.com
- 4d agoSmith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgeryfinance.yahoo.com
- 4d agoReasons to Hold HealthEquity Stock in Your Portfolio for Nowfinance.yahoo.com
- 4d agoFractyl Health Stock Up on Encouraging One-Year Revita Study Resultsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-12 | Campbell Shane Alden· SVP, Proprietary Segment | Tax withholding | 135 | $312.07 | $42,106.67 | filing |
| 2026-05-12 | Campbell Shane Alden· SVP, Proprietary Segment | Tax withholding | 84 | $312.07 | $26,316.55 | filing |
| 2026-05-12 | Campbell Shane Alden· SVP, Proprietary Segment | Option exercise | 474 | — | — | filing |
| 2026-05-12 | Campbell Shane Alden· SVP, Proprietary Segment | Option exercise | 296 | — | — | filing |
| 2026-05-04 | LAI GOLDMAN MYLA | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | Keller Deborah L | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | Joseph Molly | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | HAUGEN JANET BRUTSCHEA | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | FRIEL ROBERT F | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | Feehery William F | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | BUTHMAN MARK A | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | Pucci Paolo | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | Michels Douglas A | Award | 791 | $0.00 | $0.00 | filing |
| 2026-05-04 | Lockhart Stephen H | Award | 791 | $0.00 | $0.00 | filing |
| 2026-04-27 | Favorite Annette F· Sr. VP & Chief HR Officer | Sale | 2,817 | $305.20 | $859,753.47 | filing |
| 2026-04-27 | Winters Chad· VP, Chief Accounting Officer | Sale | 896 | $300.67 | $269,399.24 | filing |
| 2026-04-27 | Favorite Annette F· Sr. VP & Chief HR Officer | Option exercise | 2,817 | $83.47 | $235,134.99 | filing |
| 2026-04-27 | Winters Chad· VP, Chief Accounting Officer | Option exercise | 896 | $173.22 | $155,205.12 | filing |
| 2026-02-20 | Poussot Rodolphe Jean· SVP, Strategy & Corporate Dev | Tax withholding | 130 | $241.12 | $31,235.89 | filing |
| 2026-02-20 | Winters Chad· VP, Chief Accounting Officer | Tax withholding | 30 | $241.12 | $7,277.97 | filing |
| 2026-02-20 | Witherspoon Charles· VP & Treasurer | Tax withholding | 22 | $241.12 | $5,321.28 | filing |
| 2026-02-20 | Winters Chad· VP, Chief Accounting Officer | Option exercise | 89 | — | — | filing |
| 2026-02-20 | Poussot Rodolphe Jean· SVP, Strategy & Corporate Dev | Option exercise | 383 | — | — | filing |
| 2026-02-20 | Witherspoon Charles· VP & Treasurer | Option exercise | 60 | — | — | filing |
| 2026-02-18 | Green Eric Mark· President, CEO and Board Chair | Tax withholding | 574 | $248.26 | $142,389.77 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.